- Report
- April 2024
- 196 Pages
Global
From €4786EUR$4,950USD£4,111GBP
- Report
- November 2023
- 147 Pages
Global
From €2416EUR$2,499USD£2,075GBP
- Report
- December 2023
- 201 Pages
Global
€4829EUR$4,995USD£4,148GBP
- Report
- October 2023
- 145 Pages
Global
From €3045EUR$3,150USD£2,616GBP
- Report
- April 2022
- 120 Pages
Global
From €2417EUR$2,500USD£2,076GBP
- Report
- August 2022
United States
From €1876EUR$1,940USD£1,611GBP
- Report
- August 2022
Global
From €764EUR$790USD£656GBP
- Report
- February 2021
Global
From €2862EUR$2,960USD£2,458GBP
- Report
- June 2023
- 104 Pages
Global
From €3500EUR$3,878USD£3,112GBP
- Report
- September 2022
- 251 Pages
Global
From €5540EUR$5,730USD£4,758GBP
Non Melanoma Skin Cancer Drugs are a class of medications used to treat non-melanoma skin cancers, such as basal cell carcinoma and squamous cell carcinoma. These drugs are typically administered topically, and can be used to treat superficial skin cancers or to prevent recurrence of deeper skin cancers. Commonly used drugs include imiquimod, fluorouracil, and diclofenac. Other drugs, such as vismodegib, are used to treat more advanced cases of non-melanoma skin cancer.
Non Melanoma Skin Cancer Drugs are typically prescribed by dermatologists or oncologists, and are available in both generic and branded formulations. The market for these drugs is highly competitive, with many companies offering a variety of products. Some of the major players in the market include Pfizer, Novartis, Merck, and GlaxoSmithKline. Show Less Read more
